Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-

Annals of Oncology

Volumn 7, Issue 8, 1996, Pages 827-835

  Legha, S S ^a   Ring, S ^a   Bedikian, A ^a   Plager, C ^a   Eton, O ^a   Buzaid, A C ^a   Papadopoulos, N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biochemotherapy; Biotherapy; Chemotherapy; Interfeorn ; Interleukin 2; Melanoma

Indexed keywords

ALPHA INTERFERON; ANTIEMETIC AGENT; CISPLATIN; DACARBAZINE; DOPAMINE; INTERLEUKIN 2; PROCHLORPERAZINE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; HYPOTENSION; INFECTION; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0029906912     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010762     Document Type: Article

References (24)

1. Legha SS, Ring S, Papadopoulos N et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinhlastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64: 2024-9.
2. McClay EF, Mastrangelo MJ, Berd D et al. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer 1992; 50: 553-6.
3. Legha S, Ring S, Eton O et al. Durable complete responses (CRs) in metastatic melanoma treated with biochemotherapy using cisplatin + vinblastine + DTIC (CVD) and IL-2 + interferon-alpha (IFN-α). Proc Am Soc Clin Oncol 1995; 14: 412.
4. Legha SS. Interferons in the treatment of malignant melanoma. Cancer 1986; 57: 1675-7.
5. Legha SS, Papadopoulos NEJ, Plager C et al. Clinical evaluation of recombinant interferon alfa-2A (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5: 1987; 1240-6.
6. Parkinson DR, Abrams JS, Wiernik PH et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 1990; 8: 1650-6.
7. Dillman RO, Church C, Oldham RK et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. Cancer 1993; 71: 2358-70.
8. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907-13.
9. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1863-74.
10. Sparano JA, Fisher RI, Sunderland M et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969-77.
11. Keilholz U, Scheibenbogen C, Tilgen W et al. Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Cancer 1993; 72: 607-14.
12. Lee KH, Talpaz M, Rothberg JM et al. Concomitant administration of recombinant human interleukin-2 and recombinant Interferon α-2A in cancer patients: A phase I study. J Clin Oncol 1989; 7: 1726-32.
13. Flaherty LE, Redman BG, Chabot GG et al. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 1990; 65: 2471-7.
14. Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12: 806-11.
15. Demchak PA, Mier JW, Robert NJ et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study. J Clin Oncol 1991; 9: 1821-30.
16. Flaherty LE, Robinson W, Redman BG et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993; 71: 3520-5.
17. Atkins MB, O'Boyle KR, Sosman JA et al. Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994; 12: 1553-60.
18. Richards JM, Mehta N, Ramming K et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338-43.
19. Khayat D, Borel C, Tourani JM et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993; 11: 2173-80.
20. Richards J, Mehta N, Schroeder L et al. Sequential chemotherapy/immunotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 1992; 11: 346.
21. Legha S, Buzaid AC, Ring S et al. Improved results of treatment of metastatic melanoma with combined use of biotherapy and chemotherapy (biochemo). Proc Am Soc Clin Oncol 1994; 13: 394.
22. Legha S, Buzaid A, Bedikian, A et al. Efficacy of concurrent biochemotherapy using interleukin-2 (IL-2) + interferon alfa-2a (IFN) and + chemotherapy with cisplatin (C), vinblastine (V) and DTIC (D) in metastatic melanoma. Proc Am Assn Cancer Res 1994; 35: 87.
23. Creagan ET, Ahmann DL, Frytak S et al. Recombinant leukocyte A interferon (rIFN-αA) in the treatment of disseminated malignant melanoma. Cancer 1986; 58: 2576-8.
24. Whitehead RP, Figlin R, Citron ML et al. A phase II trial of concomitant human interleukin-2 and interferon-α-2a in patients with disseminated malignant melanoma. J Immunother 1993; 13: 117-21.